SCHEMBL6098546

SCHEMBL6098546

CCc1nc2ccccc2c(=O)n1Cc1ccccc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.75
PDE4B Q07343 2/20 0.75
PDE4C Q08493 2/20 0.75
PDE4D Q08499 2/20 0.75
ALDH1A1 P00352 8/20 0.62
SMN1; SMN2 Q16637 5/20 0.62
LMNA P02545 4/20 0.62
RAB9A P51151 3/20 0.62
RECQL P46063 1/20 0.62
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
POLB P06746 1/20 0.59
TLR7 Q9NYK1 1/20 0.58
MAPT P10636 2/20 0.57
CYP1A2 P05177 1/20 0.56
GAA P10253 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
TSHR P16473 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2348949 0.88 PDE4A (0.85) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL6556059 0.86 PDE4A (0.68) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL14407557 0.86 PDE4A (0.68) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL14363850 0.86 KDM4E (0.60) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL26079023 0.85 MEN1 (0.70) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL28206539 0.85 PDE4A (0.75) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL875834 0.84 PDE4A (0.54) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL3821434 0.83 TSHR (0.59) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL15106441 0.83 TSHR (0.54) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL7069119 0.82 PDE4A (0.71) PDE4APDE4BPDE4CPDE4DALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109384731-B Method for preparing quinazolinone from enol 南京理工大学 2021-10-08 CN disclosed
CN-109384731-A A method of quinazolinone is prepared by enol 南京理工大学 2019-02-26 CN disclosed
US-7053216-B2 Modulators of Rho C activity ICONIX PHARMACEUTICALS, INC. (US) 2006-05-30 US disclosed
US-20030171387-A1 Modulators of Rho C activity ENTELOS HOLDING CORP. 2003-09-11 US disclosed
WO-2003043961-A2 MODULATORS OF RHO C ACTIVITY ICONIX PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171387-A1 Modulators of Rho C activity RHOC, ROCK1, CIT PDE4A 950/4885PDE4B 1234/4885PDE4C 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.